Ulm

• Prospective, placebo-controlled clinical trial with Aconite Pain Oil in oncological patients under-going chemotherapy to prevent chemotherap … Recruiting
  2022-502889-24-00 5 2024-02-13 chemotherapy-induced polyneuropathy (CIPN)
• A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia Recruiting
  2022-502514-86-00 1 2024-02-07 Myeloproliferative Neoplasms
• Alpelisib for the treatment of lymphatic malformations associated with a PIK3CA mutation Recruiting
  2023-504146-60-00 10 2024-02-07 lymphatic malformations associated with PIK3CA mutation
• Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy … Recruiting
  2022-500531-36-00 4 2024-02-02 Type 1 diabetes mellitus
• Treatment of Established Status Epilepticus in the Elderly - a prospective, randomized, double-blind comparative effectiveness trial Recruiting
  2024-516634-35-00 6 2024-02-01 Convulsive or nonconvulsive benzodiazepine-resistant (established) sta
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac … Recruiting
  2022-502046-28-00 5 2023-12-22 HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
• A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily … Recruiting
  2022-502950-14-00 6 2023-12-08 Partial Lipodystrophy
• Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting
  2023-503582-35-00 6 2023-10-26 Staphylococcus aureus bacteremia
• Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: … Recruiting
  2023-503558-10-00 5 2023-10-13 oligometastatic pancreatic cancer
• The Pancreatic Enzymes after Gastrectomy Trial Recruiting
  2022-501944-14-00 5 2023-10-02 Patients after gastrectomy (total and partial)
• A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) … Recruiting
  2022-502160-20-00 5 2023-10-02 Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 5 2023-09-29 Newly Diagnosed Multiple Myeloma (NDMM)
• FusionVAC22_01: DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocel … Recruiting
  2022-502869-17-01 1 2023-09-26 tumor entities carrying the oncogenic driver fusion DNAJB1-PRKACA
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat … Recruiting
  2022-502851-79-00 5 2023-09-20 Active Idiopathic Inflammatory Myopathy (IIM)
• A Dose Escalation and Expansion Study of BGB-16673 in Patients with B Cell Malignancies Recruiting
  2022-502157-33-00 7 2023-09-18 B-Cell Malignancies
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient … Recruiting
  2022-501810-77-00 5 2023-09-01 Relapsed or Refractory Marginal Zone Lymphoma
• A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatr … Recruiting
  2024-511336-28-00 9 2023-08-11 Leukemia in childhood
• A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engag … Recruiting
  2022-503133-54-00 7 2023-08-09 Solid Tumors
• Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr … Recruiting
  2024-512320-11-00 5 2023-08-09 Primary diffuse large B-cell lymphoma of the central nervous system (P
• Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies Recruiting
  2022-501797-19-00 1 2023-07-13 Acute Myeloid Leukemia (AML)
• A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting
  2024-517966-40-00 4 2023-07-13 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
• A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting
  2022-500967-11-00 5 2023-07-06 Previously Untreated Metastatic or Unresectable Melanoma
• Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa) … Recruiting
  2024-511794-30-00 9 2023-06-28 Multiple Myeloma

Showing 241–264 of 569 trials